Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
17 hedge funds and large institutions have $3.12M invested in Interpace Biosciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
21% more funds holding
Funds holding: 14 → 17 (+3)
15% more capital invested
Capital invested by funds: $2.71M → $3.12M (+$411K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$199K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$45K |
| 4 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$42.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$32.8K |
| 2 |
LCC
Lincoln Capital Corp
East Greenwich,
Rhode Island
|
-$9K |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$8K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 5 |
Morgan Stanley
New York
|
-$151 |
IDXG Hedge Fund Activity: Q2 2018 in Review
17 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2018, worth a combined $3.12M — up 15% from $2.71M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IDXG positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $199K. The largest seller was Wedbush Securities, cutting an estimated $32.8K.
- 17 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2018, up from 14 in Q1 2018.
- Funds reported $3.12M of Interpace Biosciences, Inc. Common Stock stock for Q2 2018, up 15% quarter-over-quarter.
- 6 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2018 and 3 closed out, a net change of +3 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2018 was Schonfeld Strategic Advisors, an estimated $199K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2018 was Wedbush Securities, an estimated $32.8K sold.
Based on aggregated 13F filings for Q2 2018.